Doxorubicin (CAS 23214-92-8) – Anticancer API

Doxorubicin (CAS 23214-92-8) is a highly potent anticancer API belonging to the anthracycline class, renowned for its broad-spectrum antitumor activity. Its unique molecular mechanism targets cancer cell DNA, inhibiting nucleic acid synthesis and inducing apoptosis, making it effective against various malignant tumors. Produced with advanced purification technology, it maintains exceptional purity and bioactivity, complying with global pharmaceutical quality standards.

This premium API is a cornerstone for pharmaceutical manufacturers developing chemotherapeutic agents. It is widely applied in treating breast cancer, lung cancer, leukemia, and other hematological and solid tumors. With reliable stability and proven clinical efficacy, it meets the critical needs of oncology drug R&D and production, empowering healthcare providers to deliver effective cancer treatments. For researchers and pharmaceutical enterprises, it offers a trusted, high-performance raw material to advance anticancer therapy.